3-Phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-ylamine | 521300-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 3-Phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-ylamine
• 英文别名: 3-Phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-amine
• CAS: 521300-68-5
• 化学式: C₁₀H₈N₆
• 分子量: 212.214
• InChiKey: UOXLJHUXYDUVQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-ylamine 在 盐酸 作用下， 反应 0.5h， 以90%的产率得到3-phenyl-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one
  参考文献：
  名称：

  摘要：

  The replacement of the amino group with the hydroxy group was examined in the series of 6-aryl- and 6-benzoimidazolyl-7-aminoazolo[5,1-c]-1,2,4-triazines. These reactions provide a convenient synthetic procedure for the preparation of fused azolo[5,1-c]-1,2,4-triazin-7-ones.

  DOI：

  10.1023/a:1021320025860
• 作为产物：
  描述：

  Phenyl-[(2H-[1,2,4]triazol-3-yl)-hydrazono]-acetonitrile 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以81%的产率得到3-Phenyl-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-ylamine
  参考文献：
  名称：

  摘要：

  The replacement of the amino group with the hydroxy group was examined in the series of 6-aryl- and 6-benzoimidazolyl-7-aminoazolo[5,1-c]-1,2,4-triazines. These reactions provide a convenient synthetic procedure for the preparation of fused azolo[5,1-c]-1,2,4-triazin-7-ones.

  DOI：

  10.1023/a:1021320025860

文献信息

• HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145009A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
• ——
  作者：E. N. Ulomskii、S. L. Deev、T. S. Shestakova、V. L. Rusinov、O. N. Chupakhin

  DOI：10.1023/a:1021320025860

  日期：——

  The replacement of the amino group with the hydroxy group was examined in the series of 6-aryl- and 6-benzoimidazolyl-7-aminoazolo[5,1-c]-1,2,4-triazines. These reactions provide a convenient synthetic procedure for the preparation of fused azolo[5,1-c]-1,2,4-triazin-7-ones.